XML 26 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Stockholders' Equity (USD $)
Series B Perferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income/(Loss)
Noncontrolling Interest
Total
Beginning balance, Amount at Dec. 31, 2009 $ 3,321 $ 86,181 $ 36,763,984 $ (38,804,417) $ (1,376,382) $ (362,375) $ (3,689,688)
Beginning balance, Shares at Dec. 31, 2009 3,320,725 86,181,532          
Stock based compensation, Amount     259,691       259,691
Shares issued to consultants, Shares   155,000          
Shares issued to consultants, Amount   155 14,895       15,050
Debt issuance discount and waiver shares, Shares   2,250,000          
Debt issuance discount and waiver shares, Amount   2,250 200,250       202,500
Energy Enzymes, Inc. merger., Shares   1,000,000          
Energy Enzymes, Inc. merger., Amount   1,000 (502,331)     501,331 0
Issuance of shares to related party, Shares   600,000          
Issuance of shares to related party, Amount   600 161,400       162,000
Issuance of warrants     102,928       102,928
Series B to Common conversion, Shares (155,500) 155,500          
Series B to Common conversion, Amount (156) 156          
Beneficial conversion feature on related party notes     1,556,559       1,556,559
Other comprehensive income (loss)         505,461   505,461
Net loss       (8,425,253)   (138,956) (8,564,209)
Ending balance, Amount at Dec. 31, 2010 3,165 90,342 38,557,376 (47,229,670) (870,921)   (9,449,708)
Ending balance, Shares at Dec. 31, 2010 3,165,225 90,342,032          
Stock based compensation, Shares   5,585          
Stock based compensation, Amount   6 152,736       152,742
Shares issued to consultants, Shares   30,000          
Shares issued to consultants, Amount   30 24,506       24,536
Debt issuance discount and waiver shares, Shares   4,589,360          
Debt issuance discount and waiver shares, Amount   4,589 1,657,734       1,662,323
Issuance of shares to related party, Shares   29,056,356          
Issuance of shares to related party, Amount   29,056 1,423,762       1,452,818
Issuance of warrants (50) 50          
Zymetis Inc. merger, Shares   6,673,557          
Zymetis Inc. merger, Amount   6,674 1,883,461       1,890,135
Series B to Common conversion, Shares (50,000) 50,000          
Series B to Common conversion, Amount (50) 50         0
Beneficial conversion feature on related party notes     1,732,872       1,732,872
Other comprehensive income (loss)         (1,372,441)   (1,372,441)
Net loss       (18,296,359)     (18,296,359)
Ending balance, Amount at Dec. 31, 2011 $ 3,115 $ 130,747 $ 45,432,447 $ (65,526,029) $ (2,243,362) $ 0 $ (22,203,082)
Ending balance, Shares at Dec. 31, 2011 3,115,225 130,746,890